Sector News

Chiltern PCR buy cements Asia-Pacific offering

September 30, 2014
Life sciences
Chiltern has made its second significant acquisition this year snapping up fellow contract research organisation Pacific Clinical Research in a move designed to secure a stronger foothold in the Asia-Pacific region.
 
The London, UK and Wilmington, NC-based group says the addition of PCR will allow it to offer integrated services throughout the Asia-Pacific (APAC) region and strengthens in particular its offering within oncology and anti-infective areas.
 
Chiltern has been considering a means of growing capabilities in APAC for some time, because there is great interest across the industry to place more clinical trials in the region, a company spokesman told PharmaTimes.
 
“We are seeing APAC regularly in RFIs [request for information] and RFPs [request for proposal] from current and prospective customers, so this puts us in a more competitive position as a truly global service provider”, he explained. 
 
Terms of the acquisition, which follows Chiltern’s summer purchase of specialist oncology and resourcing CRO Ockham, are being kept under wraps.
 
The firm now has over 2,200 staff working across 45 countries and while no other strategic changes are immediately expected, “we are always looking for ways to improve our business and will consider other opportunities that align with the needs of our customers,” the spokesman said.
 
By Selina McKee
 
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]